Alpelisib plus endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study

被引：0

作者：

Chia, Stephen

Neven, Patrick

Ciruelos, Eva M.

Lerebours, Florence

Ruiz-Borrego, Manuel

Drullinsky, Pamela

Prat, Aleix

Park, Yeon Hee

Juric, Dejan

Turner, Nicholas C.

Chattar, Yogesh

Patino, Heather

Akdere, Murat

Rugo, Hope S.

机构：

[1] Univ British Columbia, Vancouver, BC, Canada

[2] Univ Hosp, Leuven, Belgium

[3] Hosp 12 Octubre, Med Oncol Dept, Madrid, Spain

[4] PSL Res Univ, Inst Curie, St Cloud, France

[5] Hosp Virgen Rocio Sevilla, Seville, Spain

[6] Mem Sloan Kettering Canc Ctr, New York, NY USA

[7] Hosp Clin Barcelona, Barcelona, Spain

[8] Samsung Med Ctr, Seoul, South Korea

[9] Massachusetts Gen Hosp, Boston, MA USA

[10] Royal Marsden NHS Fdn Trust, London, England

[11] Inst Canc Res, London, England

[12] Novartis Healthcare Private Ltd, Hyderabad, India

[13] Novartis Pharmaceut, E Hanover, NJ USA

[14] Novartis Pharma AG, Basel, Switzerland

[15] Univ Calif San Francisco, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1078

引用

页数：1

共 50 条

[41] Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
Omori, Yukie
Enatsu, Sotaro
Cai, Zhihong
Ishiguro, Hiroshi
BREAST CANCER, 2019, 26 (05) : 652 - 662
[42] Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
Yukie Omori
Sotaro Enatsu
Zhihong Cai
Hiroshi Ishiguro
Breast Cancer, 2019, 26 : 652 - 662
[43] Expert consensus recommendations for managing hyperglycemia and rash in patients with PK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with alpelisib (ALP)
Gallagher, Emily J.
Moore, Heather
Lacouture, Mario E.
Dent, Susan Faye
Farooki, Azeez
Goncalves, Marcus D.
Isaacs, Claudine
Johnston, Abigail
Juric, Dejan
Quandt, Zoe
Spring, Laura
Berman, Brian
Decker, Melanie
Hortobagyi, Gabriel N.
Kaffenberger, Benjamin
Kwong, Bernice Y.
Pluard, Timothy J.
Rao, Ruta D.
Schwartzberg, Lee S.
Broder, Michael S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 422 - 422
[44] Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
Goetz, Matthew P.
Okera, Meena
Wildiers, Hans
Campone, Mario
Grischke, Eva-Maria
Manso, Luis
Andre, Valerie A. M.
Chouaki, Nadia
San Antonio, Belen
Toi, Masakazu
Sledge, George W.
BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (02) : 417 - 428
[45] Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
Chia, Stephen
Ciruelos, Eva M.
Rugo, Hope S.
Lerebours, Florence
Ruiz-Borrego, Manuel
Drullinsky, Pamela
Prat, Aleix
Bachelot, Thomas
Turner, Nicholas
Gu, Ennan
Arce, Christina
Akdere, Murat
Juric, Dejan
CANCER RESEARCH, 2022, 82 (04)
[46] Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
Matthew P. Goetz
Meena Okera
Hans Wildiers
Mario Campone
Eva-Maria Grischke
Luis Manso
Valérie A. M. André
Nadia Chouaki
Belén San Antonio
Masakazu Toi
George W. Sledge
Breast Cancer Research and Treatment, 2021, 186 : 417 - 428
[47] BYLieve: A phase 2 study of alpelisib with fulvestrant or letrozole for treatment of PIK3CA mutant, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase (CDK)4/6 inhibitor therapy
Rugo, Hope S.
Turner, Nicholas
Chia, Stephen
Ciruelos, Eva
Nienstedt, Carolyn
Ridolfi, Antonia
Kong, Oliver
Sankaran, Banu
Juric, Dejan
CANCER RESEARCH, 2018, 78 (04)
[48] Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
Gelmon, Karen A.
Cristofanilli, Massimo
Rugo, Hope S.
DeMichele, Angela M.
Joy, Anil A.
Castrellon, Aurelio
Sleckman, Bethany
Mori, Ave
Theall, Kathy Puyana
Lu, Dongrui R.
Huang, Xin
Bananis, Eustratios
Finn, Richard S.
Slamon, Dennis J.
BREAST JOURNAL, 2020, 26 (03): : 368 - 375
[49] A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Mayer, Ingrid A.
Prat, Aleix
Egle, Daniel
Blau, Sibel
Perez Fidalgo, J. Alejandro
Gnant, Michael
Fasching, Peter A.
Colleoni, Marco
Wolff, Antonio C.
Winer, Eric P.
Singer, Christian F.
Hurvitz, Sara
Garcia Estevez, Laura
van Dam, Peter A.
Kuemmel, Sherko
Mundhenke, Christoph
Holmes, Frankie
Babbar, Naveen
Charbonnier, Laure
Diaz-Padilla, Ivan
Vogl, Florian D.
Sellami, Dalila
Arteaga, Carlos L.
CLINICAL CANCER RESEARCH, 2019, 25 (10) : 2975 - 2987
[50] Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Cobain, Erin F.
Hayes, Daniel F.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (32) : 3673 - +

← 1 2 3 4 5 →